175 related articles for article (PubMed ID: 2009813)
1. Principles of thrombolysis in pulmonary embolism.
Prewitt RM
Chest; 1991 Apr; 99(4 Suppl):157S-164S. PubMed ID: 2009813
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Prewitt RM; Hoy C; Kong A; Gu SA; Greenberg D; Cook R; Chan SM; Ducas J
Am Rev Respir Dis; 1990 Feb; 141(2):290-5. PubMed ID: 2105682
[TBL] [Abstract][Full Text] [Related]
3. Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis.
Prewitt RM; Gu SA; Greenberg D; Chan SM; Schick U; La Pointe H; Ducas J
J Appl Physiol (1985); 1991 Oct; 71(4):1441-6. PubMed ID: 1757368
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Werier J; Ducas J; Gu S; Chan SM; Prewitt RM
Chest; 1991 Aug; 100(2):464-9. PubMed ID: 1650681
[TBL] [Abstract][Full Text] [Related]
5. Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Prewitt RM; Downes AM; Gu SA; Chan SM; Ducas J
Chest; 1991 Mar; 99(3):708-14. PubMed ID: 1899825
[TBL] [Abstract][Full Text] [Related]
6. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Gu S; Ducas J; Patton JN; Greenberg D; Prewitt RM
Chest; 1992 Jun; 101(6):1684-90. PubMed ID: 1600792
[TBL] [Abstract][Full Text] [Related]
7. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
8. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Zhu L; Wang C; Yang Y; Wu Y; Zhai Z; Dai H; Pang B; Tong Z
J Thromb Thrombolysis; 2008 Dec; 26(3):251-6. PubMed ID: 17705052
[TBL] [Abstract][Full Text] [Related]
9. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator in acute pulmonary embolism.
Goldhaber SZ
Chest; 1989 May; 95(5 Suppl):282S-289S. PubMed ID: 2495913
[TBL] [Abstract][Full Text] [Related]
11. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.
Meneveau N; Schiele F; Vuillemenot A; Valette B; Grollier G; Bernard Y; Bassand JP
Eur Heart J; 1997 Jul; 18(7):1141-8. PubMed ID: 9243149
[TBL] [Abstract][Full Text] [Related]
12. [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature].
Mele M; Mele A; La Torre PP; Cannone M
G Ital Cardiol (Rome); 2014 Apr; 15(4):240-3. PubMed ID: 24873813
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism.
Terry KJ; Buckley LF; Aldemerdash A; Fanikos J; Dell'Orfano H
Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):132-135. PubMed ID: 28891451
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Yildiz M; Karakoyun S; Acar RD; Ozkan M
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):95-6. PubMed ID: 23037320
[TBL] [Abstract][Full Text] [Related]
15. Systemic thrombolysis for acute pulmonary embolism.
Bartel B
Hosp Pract (1995); 2015; 43(1):22-7. PubMed ID: 25559613
[TBL] [Abstract][Full Text] [Related]
16. [Hemodynamic impact of thrombolytic therapy in acute pulmonary thromboembolism].
Baruzzi AC; Knobel E; Cirenza C; Smith MR; Barbas CS; Fernandes Júnior CJ; Akamine N
Arq Bras Cardiol; 1995 Jun; 64(6):515-20. PubMed ID: 8561669
[TBL] [Abstract][Full Text] [Related]
17. PaCO(2)/ETCO(2) gradient: early indicator of thrombolysis efficacy in a massive pulmonary embolism.
Thys F; Elamly A; Marion E; Roeseler J; Janssens P; El Gariani A; Meert P; Verschuren F; Reynaert M
Resuscitation; 2001 Apr; 49(1):105-8. PubMed ID: 11334697
[TBL] [Abstract][Full Text] [Related]
18. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
Prewitt RM; Shiffman F; Greenberg D; Cook R; Ducas J
Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007
[TBL] [Abstract][Full Text] [Related]
19. Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator.
Stock KW; Jacob AL; Schnabel KJ; Bongartz G; Steinbrich W
Cardiovasc Intervent Radiol; 1997; 20(5):364-8. PubMed ID: 9271647
[TBL] [Abstract][Full Text] [Related]
20. Should thrombolytic therapy be used in patients with pulmonary embolism?
Konstantinides S
Am J Cardiovasc Drugs; 2004; 4(2):69-74. PubMed ID: 15049719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
